DE69525340T2 - Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1 - Google Patents

Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1

Info

Publication number
DE69525340T2
DE69525340T2 DE69525340T DE69525340T DE69525340T2 DE 69525340 T2 DE69525340 T2 DE 69525340T2 DE 69525340 T DE69525340 T DE 69525340T DE 69525340 T DE69525340 T DE 69525340T DE 69525340 T2 DE69525340 T2 DE 69525340T2
Authority
DE
Germany
Prior art keywords
kopolymer
compositions containing
containing copolymers
copolymer
copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69525340T
Other languages
English (en)
Other versions
DE69525340D1 (de
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69525340(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69525340D1 publication Critical patent/DE69525340D1/de
Application granted granted Critical
Publication of DE69525340T2 publication Critical patent/DE69525340T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
DE69525340T 1994-05-24 1995-05-23 Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1 Expired - Lifetime DE69525340T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
PCT/US1995/006551 WO1995031990A1 (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Publications (2)

Publication Number Publication Date
DE69525340D1 DE69525340D1 (de) 2002-03-21
DE69525340T2 true DE69525340T2 (de) 2002-09-19

Family

ID=26939072

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69525340T Expired - Lifetime DE69525340T2 (de) 1994-05-24 1995-05-23 Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1
DE2002199030 Pending DE10299030I1 (de) 1994-05-24 1995-05-23 Verbeserungen in Zusammensetzungen von kopolymeren enthaltend Kopolymer-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2002199030 Pending DE10299030I1 (de) 1994-05-24 1995-05-23 Verbeserungen in Zusammensetzungen von kopolymeren enthaltend Kopolymer-1

Country Status (31)

Country Link
US (11) US5800808A (de)
EP (1) EP0762888B1 (de)
JP (2) JPH10500955A (de)
KR (1) KR100403750B1 (de)
CN (2) CN1174753C (de)
AT (1) ATE212857T1 (de)
AU (1) AU2602195A (de)
BR (2) BR9507758A (de)
CA (1) CA2191088C (de)
CZ (1) CZ292247B6 (de)
DE (2) DE69525340T2 (de)
DK (1) DK0762888T3 (de)
EE (1) EE03423B1 (de)
ES (1) ES2172586T3 (de)
FI (1) FI120236B (de)
GE (1) GEP20002205B (de)
HK (1) HK1008657A1 (de)
HU (1) HU223473B1 (de)
IL (2) IL113812A (de)
LU (1) LU90987I2 (de)
MD (1) MD1443G2 (de)
NL (1) NL300096I2 (de)
NO (1) NO324528B1 (de)
NZ (1) NZ287335A (de)
PL (1) PL181026B1 (de)
PT (1) PT762888E (de)
SI (1) SI0762888T1 (de)
SK (1) SK283699B6 (de)
TJ (1) TJ392B (de)
UA (1) UA62908C2 (de)
WO (1) WO1995031990A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
WO1999041247A1 (en) * 1998-02-13 1999-08-19 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
JP4629229B2 (ja) 1998-09-25 2011-02-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 分子量マーカーとして用いるため、また治療用途のための共重合体１関連ポリペプチド
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
ATE329608T1 (de) * 2000-02-18 2006-07-15 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
EP1292279A4 (de) * 2000-06-05 2005-01-12 Teva Pharma Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CN100438906C (zh) * 2000-06-07 2008-12-03 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
AU6887101A (en) * 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
WO2003048735A2 (en) 2001-12-04 2003-06-12 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
AU2002353486B2 (en) * 2001-12-06 2009-01-15 Yeda Research And Development Co. Ltd Vaccine and method for treatment of motor neurone diseases
EP1455826A2 (de) * 2001-12-21 2004-09-15 Ilex Oncology, Inc. Kombination die anti-cd52 antikörper und sonstige therapeutische agenzien enthält zur behandlung von multipler sklerose
MXPA05007329A (es) 2003-01-07 2005-09-30 Yeda Res & Dev Vacuna de gotas oculares que contiene copolimero 1 para inmunizacion terapeutica.
US8008258B2 (en) * 2003-01-21 2011-08-30 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
AU2004227852B2 (en) 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
EP1684797A1 (de) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vakzine und verfahren zur behandlung von neurodegenerativen erkrankungen
DK1701730T3 (da) 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
AU2005211424A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
CA2558655A1 (en) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methods and compositions for treatment of autoimmune diseases
JP2007535498A (ja) * 2004-03-03 2007-12-06 テバ ファーマシューティカル インダストリーズ リミティド グラチラマー・アセテートおよびリルゾールでの併用療法
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
JP5495490B2 (ja) 2004-05-07 2014-05-21 アレス トレーディング エスエイ ランダム共重合体を用いる疾患の治療方法
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
CN101039691B (zh) 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
SI2361924T1 (sl) * 2004-09-09 2014-04-30 Teva Pharmaceutical Industries Ltd. Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline
HUE028833T2 (en) * 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
JP5297653B2 (ja) * 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
EP1827108B1 (de) * 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induktion der neurogenese und stammzellentherapie in kombination mit copolymer 1
AU2006211510B8 (en) * 2005-02-02 2011-04-21 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP2013628B1 (de) 2006-04-28 2016-01-06 Momenta Pharmaceuticals, Inc. Verfahren zur beurteilung von peptidmischungen
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
US9089509B2 (en) 2006-06-28 2015-07-28 Yeda Research And Development Co., Ltd. Method of treatment of age-related macular degeneration
JP2009542864A (ja) * 2006-07-05 2009-12-03 モメンタ ファーマシューティカルズ インコーポレイテッド コポリマー１の調製のための改良法
EP2174130A2 (de) 2007-06-21 2010-04-14 Momenta Pharmaceuticals, Inc. Copolymer-testverfahren
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
EP2173766A1 (de) * 2007-07-31 2010-04-14 Natco Pharma Limited Verfahren zur herstellung von glatirameracetat (copolymer-1)
NZ585367A (en) 2007-10-16 2012-12-21 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
EP2217250A4 (de) 2007-11-09 2011-01-05 California Inst Of Techn Immunmodulierende verbindungen und relevante zusammensetzungen und verfahren
US20090149541A1 (en) * 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
RU2010146489A (ru) † 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) Анализ композиций сополимера аминокислот
WO2010017292A1 (en) * 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthesis of glatiramer acetate
US8399600B2 (en) * 2008-08-07 2013-03-19 Sigma-Aldrich Co. Llc Preparation of low molecular weight polylysine and polyornithine in high yield
AR074881A1 (es) 2008-12-24 2011-02-16 Synthon Bv Un proceso para purificar una mezcla de polimeros
US8859489B2 (en) * 2009-04-03 2014-10-14 Momenta Pharmaceuticals, Inc. Water-mediated control of depolymerization step of glatiramer acetate synthesis
EP2438080B1 (de) * 2009-06-04 2013-12-04 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Verfahren für die zubereitung von copolymer-1 (cop-1) aus l-alanin, l-lysin, l-glutaminsäure und l-tyrosin zur behandlung von multipler sklerose
PT2275086E (pt) 2009-07-15 2012-05-18 Teva Pharma Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
CA2876966A1 (en) 2009-08-20 2011-02-24 Yeda Research And Development Co., Ltd. Low frequency glatiramer acetate therapy
CN102686235A (zh) 2010-01-04 2012-09-19 Mapi医药公司 包含格拉默或其药用盐的储药系统
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2523668A1 (de) 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Behandlung multipler sklerose
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
AU2011248663A1 (en) * 2010-04-27 2012-11-08 Dr. Reddy's Laboratories Ltd. Preparation of polypeptides and salts thereof
JP2013530949A (ja) 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
CA2806997A1 (en) * 2010-07-29 2012-02-02 Dr. Reddy's Laboratories Ltd. Glatiramer acetate molecular weight markers
BR112013008573A2 (pt) 2010-10-11 2016-07-12 Teva Pharma citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
WO2012123959A2 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2012150495A1 (en) 2011-05-05 2012-11-08 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CN103957705A (zh) 2011-10-10 2014-07-30 泰华制药工业有限公司 适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
EP2642290A1 (de) 2012-03-19 2013-09-25 Synthon BV Potenztest basierend auf der humanen Glatiramer-Acetatmonzytzelllinie
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
ES2529242T3 (es) 2013-03-08 2015-02-18 Teva Pharmaceutical Industries, Ltd. Dispositivo inyector reutilizable para jeringuilla
DK2774639T3 (en) 2013-03-08 2015-01-12 Teva Pharma Reusable injection device for a syringe
EP2971173A4 (de) 2013-03-14 2016-11-23 Mylan Inc Glatirameracetatreaktionsbiomarker-mrna-potenzassay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105917001B (zh) * 2013-10-24 2020-11-20 迈兰公司 用于评估醋酸格拉替雷制品的免疫学同一性的人类t细胞系试验
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016139659A1 (en) 2015-03-01 2016-09-09 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
EP3147667B1 (de) 2015-09-24 2019-06-12 CHEMI S.p.A. Analyse der molekulargewichtsverteilung von komplexen polypeptidmischungen
EP3170836B1 (de) 2015-11-23 2018-10-24 Chemi SPA Rp-hplc-analyse komplexer polypeptidmischungen
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3484441A4 (de) 2016-07-15 2020-03-18 President and Fellows of Harvard College Glycolipidzusammensetzungen und verfahren zur verwendung
JP7232752B2 (ja) 2016-08-28 2023-03-03 マピ ファーマ リミテッド 酢酸グラチラマーを含有する微小粒子を調製する方法
EP4252849A3 (de) 2016-08-31 2023-11-01 Mapi Pharma Ltd. Depotsysteme mit glatirameracetat
EP3600553A4 (de) 2017-03-26 2020-09-02 Mapi Pharma Ltd. Glatiramerdepotsysteme zur behandlung progressiver formen von multipler sklerose
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis using stem cells derived from adipose tissue
CA3062964A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
EP3765034A1 (de) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Behandlung einer herzkrankheit

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
ATE73338T1 (de) 1985-06-18 1992-03-15 Univ Emory Biologisch wirksame kopolymere.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft Fuer Industriebedarf Mbh, 6904 Eppelheim, De
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
JP3345816B2 (ja) * 1991-11-12 2002-11-18 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー コラーゲン様ポリペプチド類
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP0983020A1 (de) 1997-05-06 2000-03-08 Quanta Vision, Inc. Gewebeanalysevorrichtung
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
EE03423B1 (et) 2001-06-15
IL133890A0 (en) 2001-04-30
US6048898A (en) 2000-04-11
NL300096I1 (nl) 2002-10-01
CN1152874A (zh) 1997-06-25
PL317331A1 (en) 1997-04-01
NZ287335A (en) 1999-02-25
LU90987I2 (fr) 2003-02-25
US6362161B1 (en) 2002-03-26
ES2172586T3 (es) 2002-10-01
PT762888E (pt) 2002-07-31
SK149396A3 (en) 1997-08-06
US20050171286A1 (en) 2005-08-04
SK283699B6 (sk) 2003-12-02
US6054430A (en) 2000-04-25
NL300096I2 (nl) 2003-02-03
DE69525340D1 (de) 2002-03-21
CN1310673C (zh) 2007-04-18
CZ292247B6 (cs) 2003-08-13
NO964976D0 (no) 1996-11-22
EP0762888A1 (de) 1997-03-19
US7199098B2 (en) 2007-04-03
HU223473B1 (hu) 2004-07-28
JP2003105000A (ja) 2003-04-09
FI964600A0 (fi) 1996-11-15
US5800808A (en) 1998-09-01
EP0762888B1 (de) 2002-02-06
ATE212857T1 (de) 2002-02-15
CA2191088A1 (en) 1995-11-30
US6342476B1 (en) 2002-01-29
US7625861B2 (en) 2009-12-01
NO964976L (no) 1997-01-23
IL113812A0 (en) 1995-08-31
PL181026B1 (pl) 2001-05-31
AU2602195A (en) 1995-12-18
CN1174753C (zh) 2004-11-10
BRPI9507758B1 (pt) 2021-03-16
US20030064914A1 (en) 2003-04-03
BR9507758A (pt) 1997-09-23
UA62908C2 (uk) 2004-01-15
US20120077754A1 (en) 2012-03-29
US8367605B2 (en) 2013-02-05
WO1995031990A1 (en) 1995-11-30
DK0762888T3 (da) 2002-05-27
CN1626238A (zh) 2005-06-15
EE9600170A (et) 1997-06-16
KR970703154A (ko) 1997-07-03
MD1443G2 (ro) 2000-11-30
US20070117757A1 (en) 2007-05-24
TJ392B (en) 2004-10-13
GEP20002205B (en) 2000-08-25
FI120236B (fi) 2009-08-14
JPH10500955A (ja) 1998-01-27
US20040106554A1 (en) 2004-06-03
CA2191088C (en) 2004-09-28
SI0762888T1 (en) 2002-08-31
HK1008657A1 (en) 1999-05-14
JP3715600B2 (ja) 2005-11-09
CZ341096A3 (en) 1997-06-11
HUT75672A (en) 1997-05-28
NO324528B1 (no) 2007-11-12
US5981589A (en) 1999-11-09
MD1443F1 (en) 2000-04-30
DE10299030I1 (de) 2003-01-23
US6620847B2 (en) 2003-09-16
KR100403750B1 (ko) 2006-02-13
FI964600A (fi) 1996-12-05
EP0762888A4 (de) 1997-04-16
US6939539B2 (en) 2005-09-06
IL113812A (en) 2000-06-29
HU9603243D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
DE69525340T2 (de) Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1
WO1993009156A3 (en) Superior stain resistant compositions
ES2124479T3 (es) Composiciones biocidas.
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
DE69406766D1 (de) Polyoxymetalate-Gruppen enthaltende Organosiloxan-Zusammensetzungen
DE69208387T2 (de) Herstellung von feuchtigkeitshärtenden Organosiloxanzusammensetzungen
TW334451B (en) Composition which can be crosslinked by light
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
BR9704377A (pt) Composições de borracha contendo n,n'-bis (hidroxifenil) maleamida
ES2082074T3 (es) 1,3-difenil-2-propin-1-onas.
DE69001589T2 (de) Ca(OH)2-Zusammensetzung zur Desinfektion von Dentalkanälen.
EP0457127A3 (en) Spermicidal coating
FR2656321B1 (fr) Compositions comprenant des copolymeres d'ethylene.
CA2104079A1 (en) Hydrolyzed Zein as Hair Fixative in Hair Compositions
HUP9904128A2 (hu) Szappankészítmény
AU1228300A (en) Fabric care compositions having reduced fabric abrasion

Legal Events

Date Code Title Description
V448 Application of spc
V472 Application for supplementary protection certificate rejected